DexCom, Inc. vs J M Smucker Co — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while J M Smucker Co trades at $119.83 (market cap $12.76B). The key difference: DexCom, Inc. is far larger — about 2.5× J M Smucker Co's market cap, and J M Smucker Co pays a 3.75% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and J M Smucker Co for 74 Days on average.
| DXCM | SJM | |
|---|---|---|
Market Cap | $31.86B | $12.76B |
Volume | 3,607,070 | 1,300,545 |
Sector | Health | Consumer Staples |
52-Week High | $92.34 | $132.34 |
52-Week Low | $54.84 | $89.53 |
Typical Hold Time | 62 Days | 74 Days |
Enterprise Value | $31.32B | $19.61B |
Dividend Yield | — | 3.75% |
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth from $2.9B in 2022 to $4.66B in 2025. Profit margins have expanded significantly to 17.93%, while analyst sentiment remains overwhelmingly positive with 81% buy ratings. Recent news highlights the company's focus on Type 2 diabetes market expansion and leadership appointments.
DXCM presents a compelling growth story with expanding profitability and market opportunities, though elevated valuation multiples and technical bearish signals warrant caution. The consensus price target of $95.07 suggests 13% upside potential, but investors should monitor competitive pressures and reimbursement challenges in the CGM market.
SJM trades at $119.41, up 3.0% today, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with a consensus price target of $138.23, though high valuation ratios and recent net losses highlight fundamental challenges. Recent news highlights robust growth in segments like Uncrustables and raised fiscal 2027 guidance, but investor caution persists due to margin pressures and competitive headwinds in the consumer staples sector.
The outlook for SJM is cautiously optimistic, driven by earnings beats and strategic brand strength, but risks include volatile profitability, elevated debt, and sector competition. Upside potential exists if the company sustains revenue growth and improves net margins, aligning with analyst targets, though macroeconomic factors and execution risks could limit near-term gains.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →